Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +5.04% | +3.66% | +50.62% | +103.77% | 70.24B | |
| -0.58% | -0.30% | +35.30% | +76.06% | 62.63B | |
| -3.18% | -0.78% | -14.14% | +369.82% | 27.36B | |
| +0.16% | -0.16% | +26.73% | +12.12% | 25.71B | |
| +2.20% | -4.72% | +2.19% | -13.14% | 24.83B | |
| -1.25% | -3.33% | +17.65% | -21.55% | 19.52B | |
| -7.03% | -10.19% | +161.91% | +303.00% | 15.51B | |
| -3.91% | -5.25% | -9.16% | +485.32% | 14.66B | |
| +4.96% | +4.63% | -2.75% | +864.40% | 14.69B | |
| Average | -1.39% | -1.83% | +29.82% | +242.20% | 30.57B | |
| Weighted average by Cap. | -0.08% | -0.80% | +31.99% | +168.10% |
Employees
11
